On Friday, 6th May 2022, Lupin, pharmaceutical company announced that, it is now received the approval from the Food and Drug Administration (FDA) of the United States for the iloperidone and pregabalins tablets. The pregabalin capsules have been used for treating anxiety and epilepsy and as Iloperidone tablets have been used for the purpose of treating the symptoms of the mental disorders like the schizophrenia.
The pregabalin capsules has been marketed as a generic equivalent of the Lyrica capsules by the Upjohn US 2 LLC and according to the IQVIA and Pregabalin capsules have also estimated the annual sales of 263 million dollars in the United States for the month of March 2022 and the product is going to be manufactured at the facility of the company in the region of Aurangabad, India.
The Iloperidone tablets are also marketed by a generic equivalent of the Fanapt tablets by the company known as Vanda Pharmaceuticals and the tablets had also estimated the annual sales of 162 million dollars in the United States and Lupin also said that, the tablets are going to be manufactured at the facility of the company based in Goa, India.
The company ‘Lupin’ has been a transitional pharmaceutical company, and the company is developing and commercializing a wide range of the generic and branded formulations, along with the APIs and biotechnology products in more than 100 markets in the United States, South Africa, India and several regions across Asia Pacific (APAC), Europe, Latin America and the regions of Middle-East.
